debt_leverage_profile
Near-zero debt; cash-funded clinical-stage biotech with no material long-term debt obligations as of 2024.
Inferred
Agent_Inference
interest_rate_sensitivity
Minimal; higher rates slightly reduce interest income on cash reserves (~$20M+), no debt service impact.
Inferred
Agent_Inference
geopolitical_supply_exposure
Low intensity; China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
supply_chain_dependency
1) Single-source biological manufacturing (DM199 peptide synthesis); 2) U.S.-India API sourcing concentration risk.
Inferred
Agent_Inference
international_expansion_readiness
Pre-revenue clinical stage; no international revenue markets, so sovereign currency devaluation exposure is negligible.
Inferred
Agent_Inference
geographic_footprint
Operations primarily U.S.-based; clinical sites in U.S. and India; no material foreign currency revenue exposure.
Inferred
Agent_Inference
commodity_exposure_profile
Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
vendor_lock_dependency_score
Yes; single CDMO for DM199 manufacturing represents non-substitutable critical input with high switching cost and lead time.
Inferred
Agent_Inference
business_model_type_primary
Cloud disruption risk is low; primary operations are lab-based and CRO-dependent, not cloud-infrastructure-critical.
Inferred
Agent_Inference
business_model_type_secondary
Clinical-stage biopharma; revenue model is milestone/grant-based, not SaaS or cloud-dependent service delivery.
Inferred
Agent_Inference
switching_cost_profile
Low API coupling risk; no material third-party software APIs central to revenue model; CRO contracts are primary dependency.
Inferred
Agent_Inference
howey_test_risk_index
Low Howey risk; equity shares in a regulated biopharma; revenue model is drug commercialization, not token or investment scheme.
Inferred
Agent_Inference
regulatory_burden_tier
Very High
Medium
GICS-regulatory-overlay-v1
data_sovereignty_risk
Moderate; clinical trial patient data subject to HIPAA, GDPR (EU sites), and India PDPB; compliance infrastructure required.
Inferred
Agent_Inference
antitrust_exposure_flag
Negligible; pre-revenue niche rare disease/stroke therapy developer with no market dominance or pricing power concerns.
Inferred
Agent_Inference
regulatory_exposure_profile
Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.
Medium
GICS-regulatory-overlay-v1
revenue_model_type
0% recurring revenue currently; 100% transactional/milestone-based grants and future drug sales; no subscription revenue.
Inferred
Agent_Inference
monetization_vector
Future monetization via drug sales (licensing, co-commercialization, or direct sales of DM199 for stroke/CKD indications).
Inferred
Agent_Inference
pricing_architecture
No current pricing architecture; future DM199 pricing will follow orphan/specialty drug models (~$50K–$200K/patient/year estimated).
Inferred
Agent_Inference
pricing_power_rating
Potentially high if approved; orphan drug designation and novel mechanism support premium pricing with limited payer pushback initially.
Inferred
Agent_Inference
target_gross_margin_bracket
Post-commercialization gross margins likely 70–85%, consistent with specialty biologics after manufacturing scale-up.
Inferred
Agent_Inference
churn_vulnerability_index
Not applicable; no commercial product or subscription base; no free-rider leakage risk in current clinical-stage model.
Inferred
Agent_Inference
headcount_cost_structure
Revenue growth is not headcount-linear; commercialization could be outsourced/partnered, making scaling largely sublinear.
Inferred
Agent_Inference
marginal_cost_of_growth
Marginal cost of revenue growth is low post-approval; manufacturing scale and partnership deals drive incremental revenue.
Inferred
Agent_Inference
franchise_compliance_risk
Not applicable; DiaMedica operates no franchise network.
Inferred
Agent_Inference
customer_acquisition_metric
At 10x scale, CAC irrelevant pre-revenue; post-launch, physician/hospital adoption costs and payer coverage are key unit economics.
Inferred
Agent_Inference
network_effect_present
No network effects present; drug efficacy and clinical data drive adoption, not user-base size.
Inferred
Agent_Inference
asset_efficiency_ratio
-53.3% Return on Assets (Negative equity)
High
SEC-XBRL
recession_resistance_tier
Moderate-high resilience; stroke and CKD are non-discretionary medical needs, though payer reimbursement may tighten in downturns.
Inferred
Agent_Inference
customer_segment_primary
Hospitals and neurologists treating ischemic stroke patients; concentrated in large academic medical centers initially.
Inferred
Agent_Inference
customer_segment_secondary
Nephrologists and dialysis centers treating chronic kidney disease (CKD) patients; secondary pipeline indication target.
Inferred
Agent_Inference
characteristic_occupations
["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]
High
SOC-2018/GICS-overlay
agent_automatable_labor_share
0.32 (HIL — ~32% of characteristic roles agent-automatable)
Medium
SOC-2018 + agentic-exposure-v1
capital_expenditure_profile
8.0% CapEx / Revenue (Moderate-CapEx)
High
SEC-XBRL
sec_cik
0001401040
High
SEC-EDGAR
ticker
DMAC
High
SEC-EDGAR